RARE – Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.RARE
$22.54Name : Ultragenyx Pharmaceutical Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,174,604,544.00
EPSttm : -5.93
Ultragenyx Pharmaceutical Inc.
$22.54
2.47%$0.57Float Short %
9.58
Margin Of Safety %
Put/Call OI Ratio
0.51
EPS Next Q Diff
0.38
EPS Last/This Y
0.51
EPS This/Next Y
1.59
Price
22.54
Target Price
68.65
Analyst Recom
1.18
Performance Q
-25.34
Relative Volume
1.88
Beta
0.16
Ticker: RARE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-08 | RARE | 36.44 | 0.48 | 0.50 | 68775 |
| 2025-12-09 | RARE | 36.28 | 0.48 | 0.42 | 68761 |
| 2025-12-10 | RARE | 35.99 | 0.48 | 0.43 | 69196 |
| 2025-12-11 | RARE | 36.18 | 0.48 | 0.41 | 72429 |
| 2025-12-12 | RARE | 36.22 | 0.48 | 0.05 | 72827 |
| 2025-12-15 | RARE | 36.25 | 0.48 | 0.97 | 73038 |
| 2025-12-16 | RARE | 34.38 | 0.47 | 0.52 | 72829 |
| 2025-12-17 | RARE | 33.2 | 0.46 | 0.51 | 72824 |
| 2025-12-18 | RARE | 32.81 | 0.46 | 0.93 | 75382 |
| 2025-12-19 | RARE | 33.5 | 0.46 | 1.36 | 77758 |
| 2025-12-22 | RARE | 34.75 | 0.54 | 0.52 | 56040 |
| 2025-12-23 | RARE | 34.14 | 0.55 | 5.93 | 59644 |
| 2025-12-26 | RARE | 34.2 | 0.56 | 0.30 | 60758 |
| 2025-12-29 | RARE | 19.72 | 0.56 | 0.77 | 60811 |
| 2025-12-30 | RARE | 22.62 | 0.57 | 0.28 | 63178 |
| 2025-12-31 | RARE | 23.02 | 0.55 | 0.32 | 67066 |
| 2026-01-02 | RARE | 23.61 | 0.54 | 0.82 | 67637 |
| 2026-01-05 | RARE | 23.12 | 0.53 | 2.27 | 67148 |
| 2026-01-06 | RARE | 22.54 | 0.51 | 0.86 | 66052 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-08 | RARE | 36.45 | 11.5 | - | -5.77 |
| 2025-12-09 | RARE | 36.30 | 11.5 | - | -5.77 |
| 2025-12-10 | RARE | 35.98 | 11.5 | - | -5.77 |
| 2025-12-11 | RARE | 36.19 | 11.5 | - | -5.77 |
| 2025-12-12 | RARE | 36.22 | 11.5 | - | -5.77 |
| 2025-12-15 | RARE | 36.23 | 11.5 | - | -5.77 |
| 2025-12-16 | RARE | 36.23 | 11.5 | - | -5.77 |
| 2025-12-17 | RARE | 33.21 | 11.5 | - | -5.77 |
| 2025-12-18 | RARE | 32.84 | 11.5 | - | -5.77 |
| 2025-12-19 | RARE | 33.49 | 11.5 | - | -5.77 |
| 2025-12-22 | RARE | 34.82 | 11.5 | - | -5.77 |
| 2025-12-23 | RARE | 34.12 | 11.5 | - | -5.77 |
| 2025-12-26 | RARE | 34.20 | 11.5 | - | -5.77 |
| 2025-12-29 | RARE | 19.72 | 11.5 | - | -5.77 |
| 2025-12-30 | RARE | 22.78 | 11.5 | - | -5.77 |
| 2025-12-31 | RARE | 23.01 | 11.5 | - | -5.77 |
| 2026-01-02 | RARE | 23.60 | 11.3 | - | -5.78 |
| 2026-01-05 | RARE | 23.09 | 11.3 | - | -5.78 |
| 2026-01-06 | RARE | 22.54 | 11.3 | - | -5.78 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-08 | RARE | -0.19 | 2.64 | 8.72 |
| 2025-12-09 | RARE | -0.19 | 2.64 | 8.72 |
| 2025-12-10 | RARE | -0.19 | 2.64 | 9.88 |
| 2025-12-11 | RARE | -0.24 | 2.64 | 9.88 |
| 2025-12-12 | RARE | -0.24 | 2.64 | 9.88 |
| 2025-12-15 | RARE | -0.24 | 2.66 | 9.88 |
| 2025-12-16 | RARE | -0.24 | 2.66 | 9.88 |
| 2025-12-17 | RARE | -0.24 | 2.66 | 9.88 |
| 2025-12-18 | RARE | -0.24 | 2.66 | 9.88 |
| 2025-12-19 | RARE | -0.24 | 2.66 | 9.88 |
| 2025-12-22 | RARE | -0.24 | 2.66 | 9.88 |
| 2025-12-23 | RARE | -0.24 | 2.66 | 9.88 |
| 2025-12-26 | RARE | -0.20 | 2.66 | 9.58 |
| 2025-12-29 | RARE | -0.20 | 2.58 | 9.58 |
| 2025-12-30 | RARE | -0.20 | 2.58 | 9.58 |
| 2025-12-31 | RARE | -0.20 | 2.58 | 9.58 |
| 2026-01-02 | RARE | -0.20 | 2.58 | 9.58 |
| 2026-01-05 | RARE | -0.25 | 2.55 | 9.58 |
| 2026-01-06 | RARE | -0.25 | 2.55 | 9.58 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.81
Avg. EPS Est. Current Quarter
-1.23
Avg. EPS Est. Next Quarter
-1.43
Insider Transactions
-0.25
Institutional Transactions
2.55
Beta
0.16
Average Sales Estimate Current Quarter
187
Average Sales Estimate Next Quarter
171
Fair Value
Quality Score
26
Growth Score
50
Sentiment Score
33
Actual DrawDown %
87.1
Max Drawdown 5-Year %
-88.2
Target Price
68.65
P/E
Forward P/E
PEG
P/S
3.45
P/B
236.91
P/Free Cash Flow
EPS
-5.94
Average EPS Est. Cur. Y
-5.78
EPS Next Y. (Est.)
-4.18
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-91.95
Relative Volume
1.88
Return on Equity vs Sector %
-6357.8
Return on Equity vs Industry %
-6342.6
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1294
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading